These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 17634060)
1. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Pieribone VA; Tsai J; Soufflet C; Rey E; Shaw K; Giller E; Dulac O Epilepsia; 2007 Oct; 48(10):1870-4. PubMed ID: 17634060 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083 [TBL] [Abstract][Full Text] [Related]
3. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Shinnar S; Pellock JM; Conry JA Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174 [TBL] [Abstract][Full Text] [Related]
4. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011 [TBL] [Abstract][Full Text] [Related]
5. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453 [TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures. Sperling MR; Klein P; Tsai J Epilepsia; 2017 Apr; 58(4):558-564. PubMed ID: 28230252 [TBL] [Abstract][Full Text] [Related]
7. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. Coppola G; Grosso S; Verrotti A; Parisi P; Luchetti A; Franzoni E; Mangano S; Pelliccia A; Operto FF; Iannetti P; Curatolo P; Balestri P; Pascotto A Epilepsy Res; 2009 Feb; 83(2-3):112-6. PubMed ID: 19081227 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Kluger G; Kurlemann G; Haberlandt E; Ernst JP; Runge U; Schneider F; Makowski C; Boor R; Bast T Epilepsy Behav; 2009 Mar; 14(3):491-5. PubMed ID: 19162229 [TBL] [Abstract][Full Text] [Related]
9. Levetiracetam: a long-term follow-up study of efficacy and safety. Bauer J; Ben-Menachem E; Krämer G; Fryze W; Da Silva S; Kasteleijn-Nolst Trenité DG Acta Neurol Scand; 2006 Sep; 114(3):169-76. PubMed ID: 16911344 [TBL] [Abstract][Full Text] [Related]
10. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. Beekman M; Ungard JT; Gasior M; Carter RB; Dijkstra D; Goldberg SR; Witkin JM J Pharmacol Exp Ther; 1998 Mar; 284(3):868-77. PubMed ID: 9495844 [TBL] [Abstract][Full Text] [Related]
11. Long-term use of zonisamide in refractory childhood-onset epilepsy. Kluger G; Zsoter A; Holthausen H Eur J Paediatr Neurol; 2008 Jan; 12(1):19-23. PubMed ID: 17574461 [TBL] [Abstract][Full Text] [Related]
12. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. Reddy DS; Rogawski MA J Pharmacol Exp Ther; 2000 Sep; 294(3):909-15. PubMed ID: 10945840 [TBL] [Abstract][Full Text] [Related]
13. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM; Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886 [TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Wroe SJ; Yeates AB; Marshall A Acta Neurol Scand; 2008 Aug; 118(2):87-93. PubMed ID: 18547272 [TBL] [Abstract][Full Text] [Related]
16. Practical prescribing and long-term efficacy and safety of zonisamide. Leppik IE Epilepsy Res; 2006 Feb; 68 Suppl 2():S17-24. PubMed ID: 16406743 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review. Perry MS; Benatar M Epilepsia; 2007 Jun; 48(6):1123-7. PubMed ID: 17430408 [TBL] [Abstract][Full Text] [Related]
18. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. Genton P; Sadzot B; Fejerman N; Peltola J; Despland PA; Steinhoff B; Rektor I; Wroe S; Maubrey MC; Vandervelden C; van Hammée G; Schlit AF; van Paesschen W Acta Neurol Scand; 2006 Jun; 113(6):387-94. PubMed ID: 16674605 [TBL] [Abstract][Full Text] [Related]
19. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy. von Stuelpnagel C; Holthausen H; Kluger G Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601 [TBL] [Abstract][Full Text] [Related]
20. Tolerability of tiagabine: a prospective open-label study. Bauer J; Bergmann A; Reuber M; Stodieck SR; Genton P Epileptic Disord; 2002 Dec; 4(4):257-60. PubMed ID: 12600812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]